Studies leading up to the FDA approval found that people with hand eczema who used the cream were more likely to improve than ...

The first therapy specifically indicated for chronic hand eczema (CHE) has passed muster at the FDA.

Danish dermatology specialist Leo Pharma has scored an FDA approval that makes its JAK inhibitor cream Anzupgo (del | Despite chronic hand eczema affecting 1 in 10 people worldwide, there was no ...

LEO Pharma’s Anzupgo (delgocitinib) cream has been approved by the US Food and Drug Administration (FDA) to treat adults with ...

LEO Pharma Inc. announced today that the Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream for ...

LEO Pharma, a global leader in medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) ha ...

Privately-held Danish dermatology specialist LEO Pharma today revealed that the US Food and Drug Administration (FDA) has ...

Delgocitinib is a JAK inhibitor that blocks the activation of the JAK-STAT pathway which has been shown to play a key role in the pathophysiology of chronic inflammatory skin diseases.

LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

LEO Pharma and Boehringer Ingelheim have entered into a partnership to commercialise and advance the development of ...